$8.71
2.96% yesterday
Nasdaq, Jun 06, 10:15 pm CET
ISIN
US92556V1061
Symbol
VTRS

Viatris Stock price

$8.71
+0.23 2.71% 1M
-4.01 31.53% 6M
-3.74 30.04% YTD
-1.71 16.41% 1Y
-10.07 53.62% 5Y
-64.94 88.17% 10Y
-8.26 48.67% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.25 2.96%
ISIN
US92556V1061
Symbol
VTRS
Sector
Industry

Key metrics

Market capitalization $10.22b
Enterprise Value $23.55b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 12.72
EV/Sales (TTM) EV/Sales 1.64
P/S ratio (TTM) P/S ratio 0.71
P/B ratio (TTM) P/B ratio 0.66
Dividend yield 5.51%
Last dividend (FY24) $0.48
Revenue growth (TTM) Revenue growth -6.71%
Revenue (TTM) Revenue $14.33b
EBIT (operating result TTM) EBIT $1.52b
Free Cash Flow (TTM) Free Cash Flow $1.85b
Cash position $849.50m
EPS (TTM) EPS $-3.18
P/E forward negative
P/S forward 0.74
EV/Sales forward 1.71
Short interest 5.02%
Show more

Is Viatris a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Viatris Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Viatris forecast:

4x Buy
33%
6x Hold
50%
2x Sell
17%

Analyst Opinions

12 Analysts have issued a Viatris forecast:

Buy
33%
Hold
50%
Sell
17%

Financial data from Viatris

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
14,330 14,330
7% 7%
100%
- Direct Costs 8,500 8,500
2% 2%
59%
5,831 5,831
12% 12%
41%
- Selling and Administrative Expenses 3,480 3,480
20% 20%
24%
- Research and Development Expense 827 827
1% 1%
6%
4,391 4,391
5% 5%
31%
- Depreciation and Amortization 2,867 2,867
6% 6%
20%
EBIT (Operating Income) EBIT 1,524 1,524
3% 3%
11%
Net Profit -3,790 -3,790
6,656% 6,656%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Viatris directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viatris Stock News

Neutral
Seeking Alpha
2 days ago
Viatris Inc. (NASDAQ:VTRS ) Jefferies Global Healthcare Conference June 5, 2025 8:10 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Yuchen Ding Good morning, and welcome to the day 2 of the Jefferies Healthcare Conference.
Neutral
Business Wire
4 days ago
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”). Viatris describes itself as a “global healthcare company, which engages in the provision of healthcare and pharmac...
Neutral
GlobeNewsWire
5 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Viatris To Contact Him Directly To Discuss Their Options
More Viatris News

Company Profile

Viatris, Inc. engages in the commercialization and manufacturing of pharmaceutical products. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Head office United States
CEO Scott Smith
Employees 33,000
Founded 2019
Website www.viatris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today